Pulmonx (LUNG)

The company’s offering extends beyond the valve itself. Pulmonx markets the Chartis Pulmonary Assessment System, which helps physicians assess collateral ventilation and determine whether a patient is likely to benefit from valve therapy. It also provides the LungTraX platform, a cloud-based imaging and planning tool used to support patient selection and procedure planning. Together, these products form an integrated solution for hospitals and pulmonary specialists treating patients who remain highly symptomatic despite standard medical therapy and who may not be suitable candidates for lung volume reduction surgery.

Pulmonx sells into a specialist healthcare market that depends on clinical evidence, physician training, reimbursement access, and hospital adoption. The company operates primarily in the United States, with additional activity across Europe, the Middle East, Africa, Asia Pacific, and other international markets. Its growth prospects are tied to broader awareness of bronchoscopic lung volume reduction, expansion of trained treatment centers, and continued acceptance of minimally invasive options for advanced emphysema care.